Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GAMUNEX-C Clear all
Terminated Phase 1 Interventional

Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis

NCT01828294
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Subcutaneous immunoglobulins
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Human Normal Immunoglobulin for Subcutaneous Administration
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

NCT01465958
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
GAMUNEX-C
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Centennial, Colorado • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 2Phase 3 Interventional

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

NCT01019876
View directory record Official record
Conditions
Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
Interventions
Fludarabine, Cyclophosphamide, Busulfan, Alemtuzumab, Rabbit Anti-thymocyte Globulin, Horse Anti-thymocyte Globulin
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 2, 2026, 4:43 AM EDT
Terminated Phase 2 Interventional Results available

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

NCT02915263
View directory record Official record
Conditions
Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
Interventions
IGIV-C, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 2, 2026, 4:43 AM EDT
Withdrawn Phase 1 Interventional

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

NCT02042027
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions
Gamunex-C
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT02027701
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
IgPro20
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 2, 2026, 4:43 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

NCT00473824
View directory record Official record
Conditions
Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
Interventions
Hepatitis C Immune Globulin Intravenous (Human) 5%
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

NCT00025038
View directory record Official record
Conditions
Juvenile Myelomonocytic Leukemia
Interventions
tipifarnib, isotretinoin, fludarabine phosphate, cytarabine, radiation therapy, cyclophosphamide, anti-thymocyte globulin, allogeneic bone marrow transplantation, double-unit umbilical cord blood transplantation, umbilical cord blood transplantation, laboratory biomarker analysis
Drug · Radiation · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 2, 2026, 4:43 AM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 2Phase 3 Interventional

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

NCT03730129
View directory record Official record
Conditions
Secondary Immune Deficiency Disorder
Interventions
Hizentra
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro20
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 3 Interventional

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

NCT01804829
View directory record Official record
Conditions
Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions
Civacir® 10%
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 2, 2026, 4:43 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

NCT04044690
View directory record Official record
Conditions
Dermatomyositis
Interventions
human immunoglobulin G, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
15
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Not applicable Interventional Results available

Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT02465359
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Immune Globulin Subcutaneous (Human)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Not applicable Interventional Results available

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

NCT00606905
View directory record Official record
Conditions
Miscarriage, Recurrent, Abortion, Habitual
Interventions
Gamimune N or Gamunex 10%, normal saline
Biological · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 2, 2026, 4:43 AM EDT
Recruiting Phase 2 Interventional

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

NCT06976476
View directory record Official record
Conditions
Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired
Interventions
IgPro20
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 3 Interventional Results available

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

NCT01545076
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions
IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 2, 2026, 4:43 AM EDT
Withdrawn Phase 2 Interventional

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

NCT04450654
View directory record Official record
Conditions
Immune-Mediated Necrotizing Myopathy
Interventions
Gamunex-C, Albumin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 2, 2026, 4:43 AM EDT
Terminated Phase 2 Interventional

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

NCT00090194
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

NCT01854827
View directory record Official record
Conditions
Biliary Atresia
Interventions
Intravenous immunoglobulin (IVIG)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Days to 120 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 2, 2026, 4:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

NCT06935266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-881, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 4:43 AM EDT
Completed No phase listed Observational

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

NCT06150534
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 2, 2026, 4:43 AM EDT